{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:17:45Z","timestamp":1763727465614,"version":"build-2065373602"},"reference-count":119,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:00:00Z","timestamp":1549670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.nefro.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T01:27:22Z","timestamp":1553218042000},"page":"458-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hepatitis C y trasplante renal: el tiempo de la erradicaci\u00f3n del virus ha llegado"],"prefix":"10.1016","volume":"39","author":[{"given":"N\u00faria","family":"Esforzado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 109","key":"10.1016\/j.nefro.2019.01.002_bib0600","first-page":"S1","volume":"73","year":"2008","journal-title":"Kidney Int."},{"issue":"Suppl 7","key":"10.1016\/j.nefro.2019.01.002_bib0605","first-page":"3","volume":"15","year":"2000","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0610","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ki.1997.139","article-title":"Hepatitis C virus infection in dialysis and renal transplantation","volume":"51","author":"Pereira","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.01.002_bib0615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0272-6386(95)90617-7","article-title":"Hepatitis C virus: The nephrologist's view","volume":"25","author":"Roth","year":"1995","journal-title":"Am J Kidney Disease."},{"key":"10.1016\/j.nefro.2019.01.002_bib0620","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneph.2015.5","article-title":"Hepatitis C and its impact on renal transplantation","volume":"11","author":"Morales","year":"2015","journal-title":"Nature Rev Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0625","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ki.2014.50","article-title":"Update to hepatitis C. Review","volume":"85","author":"Fabrizi","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.01.002_bib0630","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.12848","article-title":"Manegement of hepatitis C in kidney transplant patients: On the cusp of change","volume":"14","author":"Terrault","year":"2014","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0635","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/s-0034-1371011","article-title":"Interferon \u2014 free regimens in the liver-transplant setting","volume":"34","author":"Lens","year":"2014","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.nefro.2019.01.002_bib0640","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1572-0241.1999.00788.x","article-title":"Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients","volume":"94","author":"Glicklich","year":"1999","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0645","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/17.1.129","article-title":"Severe evolution of chronic hepatitis C in renal transplantation. A case control study","volume":"17","author":"Zylberberg","year":"2002","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0650","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1086\/315355","article-title":"Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients","volume":"181","author":"Izopet","year":"2000","journal-title":"J Infect Dis."},{"key":"10.1016\/j.nefro.2019.01.002_bib0655","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/gast.2002.36610","article-title":"Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection","volume":"123","author":"Alric","year":"2002","journal-title":"Gastroenterology."},{"key":"10.1016\/j.nefro.2019.01.002_bib0660","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1600-6143.2005.00918.x","article-title":"Natural history of hepatitis C virus-related liver fibrosis after renal transplantation","volume":"5","author":"Kamar","year":"2005","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0665","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1681\/ASN.2010060668","article-title":"Clinical outcomes in hepatitis C patients before and after kidney transplantation","volume":"22","author":"Roth","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0670","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1681\/ASN.V961109","article-title":"Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant patients","volume":"9","author":"Mu\u00f1oz de Bustillo","year":"1998","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0675","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ki.1997.403","article-title":"Hepatitis C in renal transplantation. Nephrology Forum","volume":"52","author":"Vosnides","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.01.002_bib0680","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/TP.0b013e3181722f3a","article-title":"Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C","volume":"85","author":"Luan","year":"2008","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0685","unstructured":"Cortijo C. Impacto de la terapia de inducci\u00f3n con agentes biol\u00f3gicos en los resultados del trasplante renal en pacientes con infecci\u00f3n por el virus de la hepatitis C [tesis doctoral]. Universidad Europea de Madrid, Madrid; 2012."},{"key":"10.1016\/j.nefro.2019.01.002_bib0690","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0140-6736(95)92520-1","article-title":"Immunosuppression induced by hepatitis C virus infection reduces acute renal transplant rejection","volume":"346","author":"Corell","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2019.01.002_bib0695","doi-asserted-by":"crossref","first-page":"c72","DOI":"10.1159\/000089090","article-title":"Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients","volume":"102","author":"Mitwalli","year":"2006","journal-title":"Nephron Clin Pract."},{"key":"10.1016\/j.nefro.2019.01.002_bib0700","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2010.03280.x","article-title":"Long-term experience with kidney transplantation from hepatitis C positive donors into hepatitis C positive recipients","volume":"10","author":"Morales","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0705","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/TP.0b013e318225dbae","article-title":"Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation. Data from the RESITRA\/REIPI cohort","volume":"92","author":"Lopez Medrano","year":"2011","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0710","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1432-2277.2008.00694.x","article-title":"Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: Experience with kidney transplantation","volume":"21","author":"Torres","year":"2008","journal-title":"Transpant Int."},{"key":"10.1016\/j.nefro.2019.01.002_bib0715","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0720","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.meg.0000231752.50587.ae","article-title":"Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: Any role for hepatitis C infection?","volume":"18","author":"Burra","year":"2006","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0725","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry","volume":"6","author":"Caillard","year":"2006","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0730","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.tp.0000203554.54242.56","article-title":"Myeloma Hodgkin disease and lymphoid leukaemia after renal transplantation: Characteristics, risk factors and prognosis","volume":"27","author":"Caillard","year":"2006","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0735","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.3748\/wjg.v19.i44.7889","article-title":"Direct effect of hepatitis C virus on the lymphoid cells","volume":"19","author":"Kondo","year":"2013","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0740","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2169\/internalmedicine.51.8404","article-title":"Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection","volume":"51","author":"Takahashi","year":"2012","journal-title":"Intern Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib0745","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/j.1600-6143.2005.01040.x","article-title":"Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation. Meta-analysis of clinical studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0750","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000012382.97168.E0","article-title":"Association of hepatitis C with post-transplant diabetes in renal transplant patients on tacrolimus","volume":"13","author":"Bloom","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0755","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00041552-199711000-00001","article-title":"Glomerular diseases in patients with hepatitis C virus infection after renal transplantation","volume":"6","author":"Morales","year":"1997","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.nefro.2019.01.002_bib0760","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03710708","article-title":"Hepatitis C infection and chronic renal diseases","volume":"4","author":"Perico","year":"2009","journal-title":"Clin Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0765","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2215\/CJN.06920711","article-title":"Hepatitis C virus infection and kidney disease: A meta-analysis","volume":"7","author":"Fabrizi","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0770","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1681\/ASN.V7112469","article-title":"Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts","volume":"7","author":"Cruzado","year":"1996","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0775","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/00007890-199706150-00017","article-title":"Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients","volume":"63","author":"Morales","year":"1997","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0780","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1681\/ASN.V101146","article-title":"Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allografts recipients","volume":"10","author":"Baid-Agrawal","year":"1999","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0785","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00007890-199803150-00024","article-title":"Pre-transplant hepatitis C virus infection: A predictor of proteinuria after renal transplantation","volume":"65","author":"Hestin","year":"1998","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0790","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ki.2011.194","article-title":"Overlaping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection and thrombotic microangiopathy","volume":"80","author":"Baid-Agrawal","year":"2011","journal-title":"Kid Int."},{"year":"2016","series-title":"Glomerulopatia del trasplante y su relaci\u00f3n con el virus de la hepatitis C [tesis doctoral]","author":"Regidor","key":"10.1016\/j.nefro.2019.01.002_bib0795"},{"key":"10.1016\/j.nefro.2019.01.002_bib0800","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib0805","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0272-6386(97)90345-0","article-title":"The impact of renal transplantation on survival in hepatitis C positive end-stage renal disease patients","volume":"29","author":"Knoll","year":"1997","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2019.01.002_bib0810","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.1998.00883.x","article-title":"Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group","volume":"53","author":"Pereira","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.01.002_bib0815","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-6143.2004.00652.x","article-title":"Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list","volume":"5","author":"Bloom","year":"2005","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0820","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/TP.0b013e3182848de2","article-title":"Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: A systematic review and meta-analysis","volume":"95","author":"Ingsathit","year":"2013","journal-title":"Transplantation."},{"issue":"Suppl 3","key":"10.1016\/j.nefro.2019.01.002_bib0825","first-page":"72","article-title":"The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure","volume":"19","author":"Morales","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0830","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00007890-199803150-00011","article-title":"Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients","volume":"65","author":"Legendre","year":"1998","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0835","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology."},{"key":"10.1016\/j.nefro.2019.01.002_bib0840","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.tp.0000259725.96694.0a","article-title":"Hepatitis C virus infection and kidney transplantation: Predictors of patient and graft survival","volume":"83","author":"Maluf","year":"2007","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0845","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/01.TP.0000131948.29742.24","article-title":"Hepatitis C infection, time in renal-replacement therapy and outcome after kidney transplantation","volume":"78","author":"Bruchfeld","year":"2004","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0850","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/ndt\/14.10.2455","article-title":"Impaired kidney transplant survival in patients with antibodies to hepatitis C virus","volume":"94","author":"Gentil","year":"1999","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0855","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0860","first-page":"247","article-title":"The impact of hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation","volume":"11","author":"Rostami","year":"2011","journal-title":"Hepat Mon."},{"key":"10.1016\/j.nefro.2019.01.002_bib0865","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3748\/wjg.v20.i13.3410","article-title":"Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms","volume":"20","author":"Adinolfi","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0870","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: Hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepat."},{"key":"10.1016\/j.nefro.2019.01.002_bib0875","doi-asserted-by":"crossref","unstructured":"Kramer P. ten Kate F. Bijnen A. Jeekel J. Weimar W. Recombinant leucocyte interferon-A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients, Lancet. 1 1084 989-990","DOI":"10.1016\/S0140-6736(84)92327-4"},{"key":"10.1016\/j.nefro.2019.01.002_bib0880","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/ajt.12847","article-title":"Effect of HCV HIV and coinfection in kidney transplant recipients: Mate kidney analyses","volume":"14","author":"Xia","year":"2014","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0885","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ajkd.2003.09.018","article-title":"The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study","volume":"43","author":"Mahmoud","year":"2004","journal-title":"Am J Kid Dis."},{"key":"10.1016\/j.nefro.2019.01.002_bib0890","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/TP.0b013e31826fc98f","article-title":"Harmful effects of viral replication in seropositive hepatitis C virus renal transplant recipients","volume":"94","author":"Gentil Govantes","year":"2012","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0895","unstructured":"AASLD-IDSA. American Association for the Study of Liver Diseases\/Infectious Disease Society of America Joint Guidelines, Recommendations for testing, managing, and treating hepatitis C [consultado 26 Feb 2016]. Disponible en: www.hcvguidelines.org"},{"key":"10.1016\/j.nefro.2019.01.002_bib0900","unstructured":"Agencia Espa\u00f1ola de Medicamentos. Ministerio de Sanidad, Servicios Sociales e Igualdad [consultado 24 Abr 2018]. Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/#virus-hepatitisC-infecciosas"},{"key":"10.1016\/j.nefro.2019.01.002_bib0905","first-page":"2104","article-title":"Recombinant alpha interferon in renal allograft recipients with chronic hepatitis C","volume":"10","author":"Ozgur","year":"1995","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0910","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/00007890-199505270-00012","article-title":"Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients","volume":"59","author":"Rostaing","year":"1995","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0915","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"HepatitisC infection is very rarely treated among hemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0920","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/j.1600-6143.2008.02416.x","article-title":"Proceedings of Consensus Conference on simultaneous liver kidney transplantation","volume":"8","author":"Eason","year":"2008","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib0925","doi-asserted-by":"crossref","DOI":"10.1038\/nrneph.2015.5","article-title":"Hepatitis C and its impact on renal transplantation","volume":"11","author":"Morales","year":"2015","journal-title":"Nature Reviews Nephrology."},{"key":"10.1016\/j.nefro.2019.01.002_bib0930","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jvh.12276","article-title":"Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: Meta-analysis of clinical studies","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepatol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0935","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1993.03510110079036","article-title":"Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients","volume":"270","author":"Port","year":"1993","journal-title":"Jama."},{"key":"10.1016\/j.nefro.2019.01.002_bib0940","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/00007890-198802000-00031","article-title":"Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients Cytomegalovirus infection prophylaxis leading to an increase incidence of irreversible rejections","volume":"45","author":"Kovarik","year":"1988","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib0945","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrd2411","article-title":"The way forward in HCV treatment finding the right path","volume":"6","author":"Manns","year":"2007","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.nefro.2019.01.002_bib0950","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/17425255.2013.729577","article-title":"Pharmacokinetics of new oral hepatitis C antiviral drugs","volume":"9","author":"Vispo","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0955","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","article-title":"New horizons in hepatitis C antiviral therapies with direct-acting antiviral","volume":"58","author":"Aghemo","year":"2013","journal-title":"Hepatology."},{"key":"10.1016\/j.nefro.2019.01.002_bib0960","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1155\/2014\/549624","article-title":"Hepatitis C drugs: The end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: A concise review","volume":"28","author":"Yau","year":"2014","journal-title":"Can J Gastroenterol Hepatol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0965","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/ki.2013.264","article-title":"Hepatitis C treatment in patients with kidney disease","volume":"84","author":"Fabrizi","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.01.002_bib0970","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3748\/wjg.v22.i4.1650","article-title":"Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon","volume":"22","author":"Belga","year":"2016","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0975","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4254\/wjh.v8.i3.139","article-title":"Advances in hepatitis C therapy: What is the current state \u2014 what come's next? 2016 Hepatitis C Virus: Global view","volume":"8","author":"Zopf","year":"2016","journal-title":"World J Hepatol."},{"key":"10.1016\/j.nefro.2019.01.002_bib0980","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","article-title":"Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: Welcoming advances in evaluation and management","volume":"94","author":"Jadoul","year":"2018","journal-title":"Kidney Int."},{"journal-title":"J Hepatol.","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","year":"2018","key":"10.1016\/j.nefro.2019.01.002_bib0985"},{"key":"10.1016\/j.nefro.2019.01.002_bib0990","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.nefro.2019.01.002_bib0995","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2174\/138945011795378504","article-title":"ABC multidrug transporters: Target for modulation of drug pharmacokinetics in drug-drug interactions","volume":"12","author":"Marquez","year":"2011","journal-title":"Curr Drug Targets."},{"key":"10.1016\/j.nefro.2019.01.002_bib1000","first-page":"92","article-title":"Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment","volume":"23","author":"Hill","year":"2015","journal-title":"Top Antivir Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40262-015-0314-y","article-title":"Drug-drug interactions with the NS3\/4A protease inhibitor simeprevir","volume":"55","author":"Ouwerkerk-Mahadevan","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.nefro.2019.01.002_bib1010","unstructured":"Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170726138539\/anx_138539_es.pdf"},{"key":"10.1016\/j.nefro.2019.01.002_bib1015","unstructured":"Yeh WW, Feng H, Caro L. No Clinically Meaningful Pharmacokinetic Interactions Between HCV Inhibitors Grazoprevir\/Elbasvir with Tacrolimus, Mycophenolate Mofetil, and Prednisone, but Cyclosprine Increases Grazoprevir\/Elbasvir Exposures in Healthy Subjects. 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Nov 13-17, 2015, San Francisco, CA [consultado13 Feb 2016]. Disponible en: http:\/\/www.natap.org\/2015\/AASLD\/AASLD_185.htm"},{"key":"10.1016\/j.nefro.2019.01.002_bib1020","unstructured":"Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170726138516\/anx_138516_es.pdf"},{"key":"10.1016\/j.nefro.2019.01.002_bib1025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: A randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1030","doi-asserted-by":"crossref","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","author":"Reau","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.nefro.2019.01.002_bib1035","doi-asserted-by":"crossref","DOI":"10.1111\/tri.13118","article-title":"Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: A call to attention in the mid-term follow-up in a single-center cohort study","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Transplant International."},{"key":"10.1016\/j.nefro.2019.01.002_bib1040","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.29125","article-title":"Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection","volume":"66","author":"Hogan","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.nefro.2019.01.002_bib1045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOT.0000000000000198","article-title":"New hepatitis C virus therapies: Drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease","volume":"20","author":"Kwo","year":"2015","journal-title":"Curr Opin Organ Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib1050","doi-asserted-by":"crossref","unstructured":"Kwo P, Mantry P, Coakley E, Te H, Vargas H, Brown RJr et al. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450\/r\/ABT-267+ ABT-333+ ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection [Abstract O114]. 49th Annual Meeting of the European Association for the Study of the Liver (EASL). April 9-13, 2014; London, United Kingdom.","DOI":"10.1016\/S0168-8278(14)60116-1"},{"key":"10.1016\/j.nefro.2019.01.002_bib1055","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents","volume":"16","author":"Sawinsky","year":"2016","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib1060","first-page":"1474","article-title":"Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation","volume":"20","author":"Kamar","year":"2015","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib1065","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/ajt.13697","article-title":"Treatment of hepatitis C infection in renal transplant recipients: The long wait is over","volume":"16","author":"Saxena","year":"2016","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib1070","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology."},{"key":"10.1016\/j.nefro.2019.01.002_bib1075","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2019.01.002_bib1080","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1085","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2016.12.020","article-title":"Efficacy and tolerability of interferon-free antiviral therapy for kidney transplant recipients with chronic hepatitis C","volume":"66","author":"Fernandez","year":"2017","journal-title":"J Hepatol."},{"key":"10.1016\/j.nefro.2019.01.002_bib1090","doi-asserted-by":"crossref","first-page":"e0158431","DOI":"10.1371\/journal.pone.0158431","article-title":"Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection","volume":"11","author":"Lin","year":"2016","journal-title":"PLos One."},{"key":"10.1016\/j.nefro.2019.01.002_bib1095","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJM199108153250702","article-title":"Transmission of hepatitis C virus by organ transplantation","volume":"325","author":"Pereira","year":"1991","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1100","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"17","author":"Levinsky","year":"2017","journal-title":"Am J Transpl."},{"key":"10.1016\/j.nefro.2019.01.002_bib1105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199202063260612","article-title":"Transmission of HCV for organ transplantation","volume":"326","author":"Diethelm","year":"1992","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJM199302183280714","article-title":"Hepatitis C virus and renal transplantation","volume":"328","author":"Morales","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/ki.1995.29","article-title":"Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV","volume":"47","author":"Morales","year":"1995","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.01.002_bib1120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1034\/j.1399-0012.2000.14040602.x","article-title":"Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors","volume":"14","author":"Mandal","year":"2000","journal-title":"Clin Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib1125","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1046\/j.1600-6143.2004.00606.x","article-title":"The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients","volume":"4","author":"Abbott","year":"2004","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib1130","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1097\/00007890-199812270-00021","article-title":"Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation","volume":"66","author":"Ali","year":"1998","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib1135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/00007890-199510150-00004","article-title":"Hepatitis C superinfection in hepatitis C virus (HCV) infected patients transplanted with an HCV infected kidney","volume":"60","author":"Widell","year":"1995","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib1140","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/MNH.0b013e32834bba37","article-title":"Should we be using kidneys from hepatitis C virus-infected donors?","volume":"20","author":"Dominguez-Gil","year":"2011","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.nefro.2019.01.002_bib1145","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib1150","unstructured":"AASLD-IDSA. American Association for the Study of Liver Diseases\/Infectious Disease Society of America Joint Guidelines. Recommendations for testing, managing, and treating hepatitis C [consultado 26 Feb 2016]. Disponible en: www.hcvguidelines.org"},{"key":"10.1016\/j.nefro.2019.01.002_bib1155","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/TP.0000000000000479","article-title":"Shorter waitlist times and improved graft survival are observed in patients who accepted hepatitis C virus + renal allografts","volume":"99","author":"Scalea","year":"2015","journal-title":"Transplantation."},{"key":"10.1016\/j.nefro.2019.01.002_bib1160","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1681\/ASN.2017060673","article-title":"Transplantation of kidneys from HVC-positive donors: How to best use a scarce resource","volume":"28","author":"Roth","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.01.002_bib1165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C-positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1170","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1175","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: An open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: A single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefro.2019.01.002_bib1185","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.15054","article-title":"Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy","volume":"18","author":"Gupta","year":"2018","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2019.01.002_bib1190","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MNH.0000000000000456","article-title":"Expanding deceased donor kidney transplantation: Medical risk, infectious risk, hepatitis C virus, and HIV","volume":"27","author":"Ruck","year":"2018","journal-title":"Curr Opin Nephrol Hypertens."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:46Z","timestamp":1759323226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699519300396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0211699519300396"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2019.01.002","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C y trasplante renal: el tiempo de la erradicaci\u00f3n del virus ha llegado","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}